KB-1065

Tiragolumab

×
Please enable JavaScript in your browser to complete this form.
46617
Home » Antibodies » Tiragolumab

Background of Tiragolumab

TIGIT is a novel inhibitory immune checkpoint that is present on activated T cells and natural killer cells in multiple cancers. TIGIT expression has been linked with PD-1, particularly in tumor-infiltrating T cells. Tiragolumab is a fully human IgG1/kappa anti-TIGIT monoclonal antibody with an intact Fc region that blocks the binding of TIGIT to its receptor PVR. Investigators hypothesized that anti-TIGIT antibodies, such as tiragolumab, can restore antitumor response and potentially strengthen the activity of anti–PD-L1/PD-1 antibodies.

Specifications

Catalog NumberKB-1065
Antibody NameTiragolumab
IsotypeHuman IgG1,kappa
FC MuationsWild Type
TargetTIGIT
Species ReactivityHuman, Cyno
Host Cell LineEXPI CHO
Purification MethodAffinity purified
Concentration>2 mg/mL
Formulation50 mM sodium citrate,150mM NaCl,pH5.5
Purity>95% by SDS-PAGE and SEC-HPLC
ValidationELISA|FACS|KD|ADCC
Endotoxin Level<0.2 EU/mg as determined by the LAL method
Sterility0.2μm filtered
StorageIt is recommended that the protein should be aliquoted for optimal storage.
Avoid repeated freeze-thaw cycles.
StabilityStable for twelve months from date of receipt when stored at -20°C to -80°C;
Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Wang J. Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: A phase III study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations. Presented at: 2022 ASCO Annual Meeting; June 3-7, 2022; Chicago, IL. Abstract 362936.
  2. Coherus and Junshi Biosciences receive complete response Letter from US FDA for toripalimab BLA. News release. May 2, 2022. Accessed June 9, 2022.
Please enable JavaScript in your browser to complete this form.